Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
GPCR | US
-1.39
-2.88%
Healthcare
Biotechnology
30/06/2024
21/04/2026
46.83
48.06
48.62
45.76
Structure Therapeutics Inc. a clinical stage global biopharmaceutical company develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290 an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases including ANPA-0073 a biased agonist targeting apelin receptor a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578 an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. The company was founded in 2016 and is headquartered in South San Francisco California.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
High 6-Month Volatility (>65%)
Midcap (2B - 10B USD)
High Short percentage (> 15%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
54.3%1 month
66.2%3 months
57.3%6 months
159.6%-
-
2.45
0.01
0.00
-13.46
-
-
-121.84M
2.68B
2.68B
-
-
-
-
-17.69
14.11
21.89
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
11.47
Range1M
14.51
Range3M
52.05
Rel. volume
1.02
Price X volume
47.29M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| NewAmsterdam Pharma Company N.V. Ordinary Shares | NAMS | Biotechnology | 32.48 | 2.92B | -3.96% | n/a | 0.15% |
| Denali Therapeutics Inc | DNLI | Biotechnology | 20.13 | 2.88B | -2.00% | n/a | 3.51% |
| STROUDS INC | STRO | Biotechnology | 34.35 | 2.82B | -0.67% | n/a | 125.14% |
| ARCUTIS BIOTHERAPEUTICS INC. | ARQT | Biotechnology | 23.4 | 2.74B | -4.37% | n/a | 111.34% |
| Relay Therapeutics Inc. | RLAY | Biotechnology | 16.8 | 2.73B | 2.44% | n/a | 7.50% |
| IDEAYA Biosciences Inc | IDYA | Biotechnology | 31.83 | 2.69B | -5.27% | n/a | 0.20% |
| Veracyte Inc | VCYT | Biotechnology | 33.51 | 2.57B | 0.18% | n/a | 1.83% |
| BEAM THERAPEUTICS INC. | BEAM | Biotechnology | 30.69 | 2.53B | -1.60% | n/a | 19.35% |
| ADMA Biologics Inc | ADMA | Biotechnology | 10.78 | 2.51B | -0.92% | 112.71 | 75.10% |
| Zai Lab Limited | ZLAB | Biotechnology | 24.44 | 2.48B | -3.21% | n/a | 11.88% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Pitney Bowes Inc | PBI | Building Products & Equipment | 14.63 | 2.63B | 10.92% | n/a | -571.93% |
| HNI Corporation | HNI | Building Products & Equipment | 37.3 | 1.76B | -1.45% | 22.12 | 76.47% |
| ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 14.78 | 1.48B | -1.27% | n/a | 19.46% |
| Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 40.16 | 1.26B | -2.38% | 51.60 | 88.92% |
| Winnebago Industries Inc | WGO | Recreational Vehicles | 33.63 | 973.76M | 0.06% | 22.53 | 56.33% |
| Janus International Group Inc. | JBI | Building Products & Equipment | 5.51 | 800.72M | -4.17% | 11.62 | 116.21% |
| Fox Factory Holding Corp | FOXF | Recreational Vehicles | 17.6 | 733.62M | 0.11% | 42.05 | 64.69% |
| Latham Group Inc. | SWIM | Building Products & Equipment | 5.95 | 687.68M | -3.72% | 65.18 | 77.00% |
| Malibu Boats Inc | MBUU | Recreational Vehicles | 26.1 | 521.76M | -2.28% | n/a | 1.50% |
| Ennis Inc | EBF | Building Products & Equipment | 19.79 | 514.62M | 0.15% | 13.28 | 2.28% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -13.46 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.45 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 57.35 | - | Lower Risk |
| Debt to Equity | 0.01 | -1.23 | Expensive |
| Debt to Assets | 0.00 | 0.25 | Cheaper |
| Market Cap | 2.68B | - | Emerging |